Metabotropic glutamate receptors and neurodegenerative diseases

Pharmacological Research

Volumn 115, Issue , 2017, Pages 179-191

  Ribeiro, Fabiola M ^a   Vieira, Luciene B ^a   Pires, Rita G W ^b   Olmo, Roenick P ^a   Ferguson, Stephen S G ^c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Alzheimer's disease; Glutamate; Huntington's disease; mGluRs; Parkinson's disease

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; LEVODOPA; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 2 AGONIST; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 3 AGONIST; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 7; METABOTROPIC RECEPTOR 8; METABOTROPIC RECEPTOR AGONIST; N,N' DIBENZHYDRYLETHYLENEDIAMINE; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; GLUTAMIC ACID;

ALZHEIMER DISEASE; BRAIN TISSUE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; HYPERACTIVITY; INTRACELLULAR SIGNALING; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL EXCITABILITY; NERVE CELL NECROSIS; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR OCCUPANCY; REVIEW; SYNAPTIC TRANSMISSION; TISSUE DISTRIBUTION; ANIMAL; CENTRAL NERVOUS SYSTEM; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; GLUTAMIC ACID; HUMANS; NEURODEGENERATIVE DISEASES; NEUROTRANSMITTER AGENTS; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 85000788599     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.11.013     Document Type: Review

References (247)

1. [1] Ferraguti, F., Crepaldi, L., Nicoletti, F., Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol. Rev. 60:4 (2008), 536–581.
2. [2] Nakanishi, S., Masu, M., Molecular diversity and functions of glutamate receptors. Annu. Rev. Biophys. Biomol. Struct. 23 (1994), 319–348.
3. [3] Dingledine, R., Borges, K., Bowie, D., Traynelis, S.F., The glutamate receptor ion channels. Pharmacol. Rev. 51:1 (1999), 7–61.
4. [4] Pin, J.P., Galvez, T., Prezeau, L., Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol. Ther. 98:3 (2003), 325–354.
5. [5] Conn, P.J., Pin, J.P., Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacool. Toxicol. 37 (1997), 205–237.
6. [6] Gerber, U., Gee, C.E., Benquet, P., Metabotropic glutamate receptors: intracellular signaling pathways. Curr. Opin. Pharmacol. 7:1 (2007), 56–61.
7. [7] Ribeiro, F.M., Pires, R.G., Ferguson, S.S., Huntington's disease and Group I metabotropic glutamate receptors. Mol. Neurobiol. 43:1 (2011), 1–11.
8. [8] Kniazeff, J., Prezeau, L., Rondard, P., Pin, J.P., Goudet, C., Dimers and beyond: the functional puzzles of class C GPCRs. Pharmacol. Ther. 130:1 (2011), 9–25.
9. [9] Pin, J.P., Duvoisin, R., The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1 (1995), 1–26.
10. [10] Abdul-Ghani, M.A., Valiante, T.A., Carlen, P.L., Pennefather, P.S., Metabotropic glutamate receptors coupled to IP3 production mediate inhibition of IAHP in rat dentate granule neurons. J. Neurophysiol. 76:4 (1996), 2691–2700.
11. [11] Dhami, G.K., Ferguson, S.S., Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol. Ther. 111:1 (2006), 260–271.
12. [12] Schoepp, D.D., Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299:1 (2001), 12–20.
13. [13] Shigemoto, R., Nomura, S., Ohishi, H., Sugihara, H., Nakanishi, S., Mizuno, N., Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163:1 (1993), 53–57.
14. [14] Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P.J., Neki, A., Abe, T., Nakanishi, S., Mizuno, N., Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci.: Off. J. Soc. Neurosci. 17:19 (1997), 7503–7522.
15. [15] Baude, A., Nusser, Z., Roberts, J.D., Mulvihill, E., McIlhinney, R.A., Somogyi, P., The metabotropic glutamate receptor (mGluR1 alpha) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction. Neuron 11:4 (1993), 771–787.
16. [16] Lujan, R., Nusser, Z., Roberts, J.D., Shigemoto, R., Somogyi, P., Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur. J. Neurosci. 8:7 (1996), 1488–1500.
17. [17] Martin, L.J., Blackstone, C.D., Huganir, R.L., Price, D.L., Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron 9:2 (1992), 259–270.
18. [18] Shigemoto, R., Nakanishi, S., Mizuno, N., Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J. Comp. Neurol. 322:1 (1992), 121–135.
19. [19] Hubert, G.W., Paquet, M., Smith, Y., Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey Substantia nigra. J. Neurosc.: Off. J. Soc. Neurosci. 21:6 (2001), 1838–1847.
20. [20] Abe, T., Sugihara, H., Nawa, H., Shigemoto, R., Mizuno, N., Nakanishi, S., Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J. Biol. Chem. 267:19 (1992), 13361–13368.
21. [21] Romano, C., Sesma, M.A., McDonald, C.T., O'Malley, K., Van den Pol, A.N., Olney, J.W., Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 355:3 (1995), 455–469.
22. [22] Vidnyanszky, Z., Hamori, J., Negyessy, L., Ruegg, D., Knopfel, T., Kuhn, R., Gorcs, T.J., Cellular and subcellular localization of the mGluR5a metabotropic glutamate receptor in rat spinal cord. Neuroreport 6:1 (1994), 209–213.
23. [23] Berthele, A., Boxall, S.J., Urban, A., Anneser, J.M., Zieglgansberger, W., Urban, L., Tolle, T.R., Distribution and developmental changes in metabotropic glutamate receptor messenger RNA expression in the rat lumbar spinal cord, brain research. Dev. Brain Res. 112:1 (1999), 39–53.
24. [24] Jia, H., Rustioni, A., Valtschanoff, J.G., Metabotropic glutamate receptors in superficial laminae of the rat dorsal horn. J. Comp. Neurol. 410:4 (1999), 627–642.
25. [25] Ohishi, H., Shigemoto, R., Nakanishi, S., Mizuno, N., Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 53:4 (1993), 1009–1018.
26. [26] Ohishi, H., Ogawa-Meguro, R., Shigemoto, R., Kaneko, T., Nakanishi, S., Mizuno, N., Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortex. Neuron 13:1 (1994), 55–66.
27. [27] Ohishi, H., Shigemoto, R., Nakanishi, S., Mizuno, N., Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J. Comp. Neurol. 335:2 (1993), 252–266.
28. [28] Tanabe, Y., Nomura, A., Masu, M., Shigemoto, R., Mizuno, N., Nakanishi, S., Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J. Neurosci.: Off. J. Soc. Neurosci. 13:4 (1993), 1372–1378.
29. [29] Testa, C.M., Standaert, D.G., Young, A.B., Penney, J.B. Jr., Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci.: Off. J. Soc. Neurosci. 14:Pt. 2 (5) (1994), 3005–3018.
30. [30] Petralia, R.S., Wang, Y.X., Niedzielski, A.S., Wenthold, R.J., The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 71:4 (1996), 949–976.
31. [31] Tamaru, Y., Nomura, S., Mizuno, N., Shigemoto, R., Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 106:3 (2001), 481–503.
32. [32] Nakajima, Y., Iwakabe, H., Akazawa, C., Nawa, H., Shigemoto, R., Mizuno, N., Nakanishi, S., Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J. Biol. Chem. 268:16 (1993), 11868–11873.
33. [33] Kinoshita, A., Shigemoto, R., Ohishi, H., van der Putten, H., Mizuno, N., Immunohistochemical localization of metabotropic glutamate receptors, mGluR7a and mGluR7b, in the central nervous system of the adult rat and mouse: a light and electron microscopic study. J. Comp. Neurol. 393:3 (1998), 332–352.
34. [34] Kinoshita, A., Ohishi, H., Nomura, S., Shigemoto, R., Nakanishi, S., Mizuno, N., Presynaptic localization of a metabotropic glutamate receptor, mGluR4a, in the cerebellar cortex: a light and electron microscope study in the rat. Neurosci. Lett. 207:3 (1996), 199–202.
35. [35] Fotuhi, M., Standaert, D.G., Testa, C.M., Penney, J.B. Jr., Young, A.B., Differential expression of metabotropic glutamate receptors in the hippocampus and entorhinal cortex of the rat, Brain research. Mol. Brain Res. 21:3–4 (1994), 283–292.
36. [36] Makoff, A., Volpe, F., Lelchuk, R., Harrington, K., Emson, P., Molecular characterization and localization of human metabotropic glutamate receptor type 3, brain research. Mol. Brain Res. 40:1 (1996), 55–63.
37. [37] Azkue, J.J., Murga, M., Fernandez-Capetillo, O., Mateos, J.M., Elezgarai, I., Benitez, R., Osorio, A., Diez, J., Puente, N., Bilbao, A., Bidaurrazaga, A., Kuhn, R., Grandes, P., Immunoreactivity for the group III metabotropic glutamate receptor subtype mGluR4a in the superficial laminae of the rat spinal dorsal horn. J. Comp. Neurol. 430:4 (2001), 448–457.
38. [38] Corti, C., Aldegheri, L., Somogyi, P., Ferraguti, F., Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS. Neuroscience 110:3 (2002), 403–420.
39. [39] Duvoisin, R.M., Zhang, C., Ramonell, K., A novel metabotropic glutamate receptor expressed in the retina and olfactory bulb. J. Neurosci.: Off. J. Soc. Neurosci. 15:4 (1995), 3075–3083.
40. [40] Saugstad, J.A., Kinzie, J.M., Shinohara, M.M., Segerson, T.P., Westbrook, G.L., Cloning and expression of rat metabotropic glutamate receptor 8 reveals a distinct pharmacological profile. Mol. Pharmacol. 51:1 (1997), 119–125.
41. [41] Corti, C., Restituito, S., Rimland, J.M., Brabet, I., Corsi, M., Pin, J.P., Ferraguti, F., Cloning and characterization of alternative mRNA forms for the rat metabotropic glutamate receptors mGluR7 and mGluR8. Eur. J. Neurosci. 10:12 (1998), 3629–3641.
42. [42] Mineff, E., Valtschanoff, J., Metabotropic glutamate receptors 2 and 3 expressed by astrocytes in rat ventrobasal thalamus. Neurosci. Lett. 270:2 (1999), 95–98.
43. [43] Condorelli, D.F., Dell'Albani, P., Corsaro, M., Giuffrida, R., Caruso, A., Trovato Salinaro, A., Spinella, F., Nicoletti, F., Albanese, V., Giuffrida Stella, A.M., Metabotropic glutamate receptor expression in cultured rat astrocytes and human gliomas. Neurochem. Res. 22:9 (1997), 1127–1133.
44. [44] Biber, K., Laurie, D.J., Berthele, A., Sommer, B., Tolle, T.R., Gebicke-Harter, P.J., van Calker, D., Boddeke, H.W., Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J. Neurochem. 72:4 (1999), 1671–1680.
45. [45] Schools, G.P., Kimelberg, H.K., mGluR3 and mGluR5 are the predominant metabotropic glutamate receptor mRNAs expressed in hippocampal astrocytes acutely isolated from young rats. J. Neurosci. Res. 58:4 (1999), 533–543.
46. [46] Aronica, E., van Vliet, E.A., Mayboroda, O.A., Troost, D., da Silva, F.H., Gorter, J.A., Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. Eur. J. Neurosci. 12:7 (2000), 2333–2344.
47. [47] Ferraguti, F., Corti, C., Valerio, E., Mion, S., Xuereb, J., Activated astrocytes in areas of kainate-induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5. Exp. Brain Res. 137:1 (2001), 1–11.
48. [48] Dolan, S., Kelly, J.G., Monteiro, A.M., Nolan, A.M., Up-regulation of metabotropic glutamate receptor subtypes 3 and 5 in spinal cord in a clinical model of persistent inflammation and hyperalgesia. Pain 106:3 (2003), 501–512.
49. [49] Silva, G.A., Theriault, E., Mills, L.R., Pennefather, P.S., Feeney, C.J., Group I and II metabotropic glutamate receptor expression in cultured rat spinal cord astrocytes. Neurosci. Lett. 263:2–3 (1999), 117–120.
50. [50] Besong, G., Battaglia, G., D'Onofrio, M., Di Marco, R., Ngomba, R.T., Storto, M., Castiglione, M., Mangano, K., Busceti, C.L., Nicoletti, F.R., Bacon, K., Tusche, M., Valenti, O., Conn, P.J., Bruno, V., Nicoletti, F., Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J. Neurosci.: Off. J. Soc. Neurosci. 22:13 (2002), 5403–5411.
51. [51] Ciccarelli, R., Sureda, F.X., Casabona, G., Di Iorio, P., Caruso, A., Spinella, F., Condorelli, D.F., Nicoletti, F., Caciagli, F., Opposite influence of the metabotropic glutamate receptor subtypes mGlu3 and −5 on astrocyte proliferation in culture. Glia 21:4 (1997), 390–398.
52. [52] Taylor, D.L., Diemel, L.T., Pocock, J.M., Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J. Neurosci.: Off. J. Soc. Neurosci. 23:6 (2003), 2150–2160.
53. [53] Taylor, D.L., Jones, F., Kubota, E.S., Pocock, J.M., Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J. Neurosci.: Off. J. Soc. Neurosci. 25:11 (2005), 2952–2964.
54. [54] Taylor, D.L., Diemel, L.T., Cuzner, M.L., Pocock, J.M., Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer's disease. J. Neurochem. 82:5 (2002), 1179–1191.
55. [55] Zhang, Y., Chen, K., Sloan, S.A., Bennett, M.L., Scholze, A.R., O'Keeffe, S., Phatnani, H.P., Guarnieri, P., Caneda, C., Ruderisch, N., Deng, S., Liddelow, S.A., Zhang, C., Daneman, R., Maniatis, T., Barres, B.A., Wu, J.Q., An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci.: Off. J. Soc. Neurosci. 34:36 (2014), 11929–11947.
56. [56] Hermans, E., Challiss, R.A., Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem. J. 359:Pt. 3 (2001), 465–484.
57. [57] Lu, W.Y., Xiong, Z.G., Lei, S., Orser, B.A., Dudek, E., Browning, M.D., MacDonald, J.F., G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat. Neurosci. 2:4 (1999), 331–338.
58. [58] Alagarsamy, S., Marino, M.J., Rouse, S.T., Gereau, R.W.t., Heinemann, S.F., Conn, P.J., Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat. Neurosci. 2:3 (1999), 234–240.
59. [59] Heidinger, V., Manzerra, P., Wang, X.Q., Strasser, U., Yu, S.P., Choi, D.W., Behrens, M.M., Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J. Neurosci.: Off. J. Soc. Neurosci. 22:13 (2002), 5452–5461.
60. [60] Tu, J.C., Xiao, B., Yuan, J.P., Lanahan, A.A., Leoffert, K., Li, M., Linden, D.J., Worley, P.F., Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron 21:4 (1998), 717–726.
61. [61] Tu, J.C., Xiao, B., Naisbitt, S., Yuan, J.P., Petralia, R.S., Brakeman, P., Doan, A., Aakalu, V.K., Lanahan, A.A., Sheng, M., Worley, P.F., Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23:3 (1999), 583–592.
62. [62] Husi, H., Ward, M.A., Choudhary, J.S., Blackstock, W.P., Grant, S.G., Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat. Neurosci. 3:7 (2000), 661–669.
63. [63] Rong, R., Ahn, J.Y., Huang, H., Nagata, E., Kalman, D., Kapp, J.A., Tu, J., Worley, P.F., Snyder, S.H., Ye, K., PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat. Neurosci. 6:11 (2003), 1153–1161.
64. [64] Hou, L., Klann, E., Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci.: Offi. J. Soc. Neurosci. 24:28 (2004), 6352–6361.
65. [65] Mao, L., Yang, L., Tang, Q., Samdani, S., Zhang, G., Wang, J.Q., The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. J. Neurosci.: Offi. J. Soc. Neurosci. 25:10 (2005), 2741–2752.
66. [66] Nicodemo, A.A., Pampillo, M., Ferreira, L.T., Dale, L.B., Cregan, T., Ribeiro, F.M., Ferguson, S.S., Pyk2 uncouples metabotropic glutamate receptor G protein signaling but facilitates ERK1/2 activation. Mol. brain, 3, 2010, 4.
67. [67] Balazs, R., Trophic effect of glutamate. Curr. Top. Med. Chem. 6:10 (2006), 961–968.
68. [68] Choe, E.S., Wang, J.Q., Group I metabotropic glutamate receptor activation increases phosphorylation of cAMP response element-binding protein, Elk-1, and extracellular signal-regulated kinases in rat dorsal striatum, Brain research. Mol. Brain Research 94:1–2 (2001), 75–84.
69. [69] Miller, S., Romano, C., Cotman, C.W., Growth factor upregulation of a phosphoinositide-coupled metabotropic glutamate receptor in cortical astrocytes. J. Neurosci.: Offi. J. Soc. Neurosci. 15:9 (1995), 6103–6109.
70. [70] Pasti, L., Volterra, A., Pozzan, T., Carmignoto, G., Intracellular calcium oscillations in astrocytes: a highly plastic, bidirectional form of communication between neurons and astrocytes in situ. J. Neurosci.: Offi. J. Soc. Neurosci. 17:20 (1997), 7817–7830.
71. [71] Paquet, M., Ribeiro, F.M., Guadagno, J., Esseltine, J.L., Ferguson, S.S., Cregan, S.P., Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis. Mol. Brain, 6, 2013, 9.
72. [72] Servitja, J.M., Masgrau, R., Sarri, E., Picatoste, F., Group I metabotropic glutamate receptors mediate phospholipase D stimulation in rat cultured astrocytes. J. Neurochem. 72:4 (1999), 1441–1447.
73. [73] Peavy, R.D., Conn, P.J., Phosphorylation of mitogen-activated protein kinase in cultured rat cortical glia by stimulation of metabotropic glutamate receptors. J. Neurochem. 71:2 (1998), 603–612.
74. [74] Byrnes, K.R., Stoica, B., Loane, D.J., Riccio, A., Davis, M.I., Faden, A.I., Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 57:5 (2009), 550–560.
75. [75] Sharon, D., Vorobiov, D., Dascal, N., Positive and negative coupling of the metabotropic glutamate receptors to a G protein-activated K+ channel, GIRK, in Xenopus oocytes. J. Gen. Physiol. 109:4 (1997), 477–490.
76. [76] Iacovelli, L., Bruno, V., Salvatore, L., Melchiorri, D., Gradini, R., Caricasole, A., Barletta, E., De Blasi, A., Nicoletti, F., Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. J. Neurochem. 82:2 (2002), 216–223.
77. [77] Ferraguti, F., Baldani-Guerra, B., Corsi, M., Nakanishi, S., Corti, C., Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur. J. Neurosci. 11:6 (1999), 2073–2082.
78. [78] Jiang, Q., Yan, Z., Feng, J., Activation of group III metabotropic glutamate receptors attenuates rotenone toxicity on dopaminergic neurons through a microtubule-dependent mechanism. J. Neurosci.: Offi. J. Soc. Neurosci. 26:16 (2006), 4318–4328.
79. [79] Gu, Z., Liu, W., Wei, J., Yan, Z., Regulation of N-methyl-D-aspartic acid (NMDA) receptors by metabotropic glutamate receptor 7. J. Biol. Chem. 287:13 (2012), 10265–10275.
80. [80] Bruno, V., Battaglia, G., Casabona, G., Copani, A., Caciagli, F., Nicoletti, F., Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci.: Offi. J. Soc. Neurosci. 18:23 (1998), 9594–9600.
81. [81] D'Onofrio, M., Cuomo, L., Battaglia, G., Ngomba, R.T., Storto, M., Kingston, A.E., Orzi, F., De Blasi, A., Di Iorio, P., Nicoletti, F., Bruno, V., Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J. Neurochem. 78:3 (2001), 435–445.
82. [82] Aronica, E., Gorter, J.A., Ijlst-Keizers, H., Rozemuller, A.J., Yankaya, B., Leenstra, S., Troost, D., Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur. J. Neurosci. 17:10 (2003), 2106–2118.
83. [83] Ciccarelli, R., D'Alimonte, I., Ballerini, P., D'Auro, M., Nargi, E., Buccella, S., Di Iorio, P., Bruno, V., Nicoletti, F., Caciagli, F., Molecular signalling mediating the protective effect of A1 adenosine and mGlu3 metabotropic glutamate receptor activation against apoptosis by oxygen/glucose deprivation in cultured astrocytes. Mol. Pharmacol. 71:5 (2007), 1369–1380.
84. [84] Ciccarelli, R., Di Iorio, P., Giuliani, P., D'Alimonte, I., Ballerini, P., Caciagli, F., Rathbone, M.P., Rat cultured astrocytes release guanine-based purines in basal conditions and after hypoxia/hypoglycemia. Glia 25:1 (1999), 93–98.
85. [85] Matarredona, E.R., Santiago, M., Venero, J.L., Cano, J., Machado, A., Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction. J. Neurochem. 76:2 (2001), 351–360.
86. [86] Battaglia, G., Molinaro, G., Riozzi, B., Storto, M., Busceti, C.L., Spinsanti, P., Bucci, D., Di Liberto, V., Mudo, G., Corti, C., Corsi, M., Nicoletti, F., Belluardo, N., Bruno, V., Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons. PLoS One, 4(8), 2009, e6591.
87. [87] Venero, J.L., Santiago, M., Tomas-Camardiel, M., Matarredona, E.R., Cano, J., Machado, A., DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury. Neuroscience 113:4 (2002), 857–869.
88. [88] Goedert, M., Spillantini, M.G., A century of Alzheimer's disease. Science 314:5800 (2006), 777–781.
89. [89] Alzheimer's, A., 2014 Alzheimer's disease facts and figures. Alzheimer's Dementia: J. Alzheimer's Assoc. 10:2 (2014), e47–e92.
90. [90] Palop, J.J., Chin, J., Mucke, L., A network dysfunction perspective on neurodegenerative diseases. Nature 443:7113 (2006), 768–773.
91. [91] Gomez-Isla, T., Price, J.L., McKeel, D.W. Jr., Morris, J.C., Growdon, J.H., Hyman, B.T., Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci.: Offi. J. Soc. Neurosci. 16:14 (1996), 4491–4500.
92. [92] Glenner, G.G., Wong, C.W., Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:3 (1984), 885–890.
93. [93] Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M., Binder, L.I., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 3:13 (1986), 4913–4917.
94. [94] Masters, C.L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R.N., Beyreuther, K., Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4:11 (1985), 2757–2763.
95. [95] Selkoe, D.J., The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8:11 (1998), 447–453.
96. [96] Zhang, Y.W., Thompson, R., Zhang, H., Xu, H., APP processing in Alzheimer's disease. Mol. Brain, 4, 2011, 3.
97. [97] Yan, Y., Wang, C., Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. J. Mol. Biol. 364:5 (2006), 853–862.
98. [98] Hardy, J.A., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis. Science 256:5054 (1992), 184–185.
99. [99] Selkoe, D.J., Toward a comprehensive theory for Alzheimer's disease. Hypothesis: alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N. Y. Acad. Sci. 924 (2000), 17–25.
100. [100] Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., Wals, P., Zhang, C., Finch, C.E., Krafft, G.A., Klein, W.L., Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95:11 (1998), 6448–6453.
101. [101] Walsh, D.M., Selkoe, D.J., A beta oligomers − a decade of discovery. J. Neurochem. 101:5 (2007), 1172–1184.
102. [102] Lustbader, J.W., Cirilli, M., Lin, C., Xu, H.W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., Trinchese, F., Liu, S., Gunn-Moore, F., Lue, L.F., Walker, D.G., Kuppusamy, P., Zewier, Z.L., Arancio, O., Stern, D., Yan, S.S., Wu, H., ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304:5669 (2004), 448–452.
103. [103] Berridge, M.J., Calcium regulation of neural rhythms, memory and Alzheimer's disease. J. Physiol. 592:2 (2014), 281–293.
104. [104] Demuro, A., Parker, I., Stutzmann, G.E., Calcium signaling and amyloid toxicity in Alzheimer disease. J. Biol. Chem. 285:17 (2010), 12463–12468.
105. [105] Blanchard, B.J., Thomas, V.L., Ingram, V.M., Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. Biochem. Biophys. Res. Commun. 293:4 (2002), 1197–1203.
106. [106] Roth, A.D., Ramirez, G., Alarcon, R., Von Bernhardi, R., Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol. Res. 38:4 (2005), 381–387.
107. [107] Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., Mechanisms underlying inflammation in neurodegeneration. Cell 140:6 (2010), 918–934.
108. [108] Varadarajan, S., Yatin, S., Aksenova, M., Butterfield, D.A., Review: alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130:2-3 (2000), 184–208.
109. [109] Guglielmotto, M., Giliberto, L., Tamagno, E., Tabaton, M., Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front. Aging Neurosci., 2, 2010, 3.
110. [110] Lacor, P.N., Buniel, M.C., Chang, L., Fernandez, S.J., Gong, Y., Viola, K.L., Lambert, M.P., Velasco, P.T., Bigio, E.H., Finch, C.E., Krafft, G.A., Klein, W.L., Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J. Neurosci.: Offi. J. Soc. Neurosci. 24:45 (2004), 10191–10200.
111. [111] Niswender, C.M., Conn, P.J., Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacool. Toxicol. 50 (2010), 295–322.
112. [112] Snyder, E.M., Nong, Y., Almeida, C.G., Paul, S., Moran, T., Choi, E.Y., Nairn, A.C., Salter, M.W., Lombroso, P.J., Gouras, G.K., Greengard, P., Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8:8 (2005), 1051–1058.
113. [113] Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., Malinow, R., AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52:5 (2006), 831–843.
114. [114] Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., Sabatini, B.L., Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci.: Offi. J. Soc. Neurosci. 27:11 (2007), 2866–2875.
115. [115] Renner, M., Lacor, P.N., Velasco, P.T., Xu, J., Contractor, A., Klein, W.L., Triller, A., Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66:5 (2010), 739–754.
116. [116] Chen, X., Lin, R., Chang, L., Xu, S., Wei, X., Zhang, J., Wang, C., Anwyl, R., Wang, Q., Enhancement of long-term depression by soluble amyloid beta protein in rat hippocampus is mediated by metabotropic glutamate receptor and involves activation of p38MAPK, STEP and caspase-3. Neuroscience 253 (2013), 435–443.
117. [117] Caraci, F., Battaglia, G., Sortino, M.A., Spampinato, S., Molinaro, G., Copani, A., Nicoletti, F., Bruno, V., Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?. Neurochem. Int. 1:4 (2012), 559–565.
118. [118] Albasanz, J.L., Dalfo, E., Ferrer, I., Martin, M., Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Neurobiol. Dis. 20:3 (2005), 685–693.
119. [119] Kammermeier, P.J., Xiao, B., Tu, J.C., Worley, P.F., Ikeda, S.R., Homer proteins regulate coupling of group I metabotropic glutamate receptors to N-type calcium and M-type potassium channels. J. Neurosci.: Offi. J. Soc. Neurosci. 20:19 (2000), 7238–7245.
120. [120] Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L., Selkoe, D.J., Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14:8 (2008), 837–842.
121. [121] Kim, J.H., Anwyl, R., Suh, Y.H., Djamgoz, M.B., Rowan, M.J., Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J. Neurosci.: Offi. J. Soc. Neurosci. 21:4 (2001), 1327–1333.
122. [122] Fitzjohn, S.M., Palmer, M.J., May, J.E., Neeson, A., Morris, S.A., Collingridge, G.L., A characterisation of long-term depression induced by metabotropic glutamate receptor activation in the rat hippocampus in vitro. J. Physiol. 537:Pt. 2 (2001), 421–430.
123. [123] Volk, L.J., Daly, C.A., Huber, K.M., Differential roles for group 1 mGluR subtypes in induction and expression of chemically induced hippocampal long-term depression. J. Neurophysiol. 95:4 (2006), 2427–2438.
124. [124] Um, J.W., Kaufman, A.C., Kostylev, M., Heiss, J.K., Stagi, M., Takahashi, H., Kerrisk, M.E., Vortmeyer, A., Wisniewski, T., Koleske, A.J., Gunther, E.C., Nygaard, H.B., Strittmatter, S.M., Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79:5 (2013), 887–902.
125. [125] Hamilton, A., Zamponi, G.W., Ferguson, S.S., Glutamate receptors function as scaffolds for the regulation of beta-amyloid and cellular prion protein signaling complexes. Mol. Brain, 8, 2015, 18.
126. [126] Hamilton, A., Esseltine, J.L., DeVries, R.A., Cregan, S.P., Ferguson, S.S., Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. Mol. Brain, 7, 2014, 40.
127. [127] De Felice, F.G., Velasco, P.T., Lambert, M.P., Viola, K., Fernandez, S.J., Ferreira, S.T., Klein, W.L., Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 282:15 (2007), 11590–11601.
128. [128] Hamilton, A., Vasefi, M., Vander Tuin, C., McQuaid, R.J., Anisman, H., Ferguson, S.S., Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an alzheimer disease mouse model. Cell Rep. 15:9 (2016), 1859–1865.
129. [129] Rebeck, G.W., Hoe, H.S., Moussa, C.E., Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J. Biol. Chem. 285:10 (2010), 7440–7446.
130. [130] Casley, C.S., Lakics, V., Lee, H.G., Broad, L.M., Day, T.A., Cluett, T., Smith, M.A., O'Neill, M.J., Kingston, A.E., Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-beta peptide. Brain Res. 1260 (2009), 65–75.
131. [131] Caraci, F., Molinaro, G., Battaglia, G., Giuffrida, M.L., Riozzi, B., Traficante, A., Bruno, V., Cannella, M., Merlo, S., Wang, X., Heinz, B.A., Nisenbaum, E.S., Britton, T.C., Drago, F., Sortino, M.A., Copani, A., Nicoletti, F., Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol. Pharmacol. 79:3 (2011), 618–626.
132. [132] Lee, H.G., Ogawa, O., Zhu, X., O'Neill, M.J., Petersen, R.B., Castellani, R.J., Ghanbari, H., Perry, G., Smith, M.A., Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer's disease. Acta Neuropathol. (Berl.) 107:4 (2004), 365–371.
133. [133] Bruno, V., Sureda, F.X., Storto, M., Casabona, G., Caruso, A., Knopfel, T., Kuhn, R., Nicoletti, F., The neuroprotective activity of group-II metabotropic glutamate receptors requires new protein synthesis and involves a glial-neuronal signaling. J. Neurosci.: Offi. J. Soc. Neurosci. 17:6 (1997), 1891–1897.
134. [134] Kim, S.H., Fraser, P.E., Westaway, D., St George-Hyslop, P.H., Ehrlich, M.E., Gandy, S., Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals. J. Neurosci.: Offi. J. Soc. Neurosci. 30:11 (2010), 3870–3875.
135. [135] Yoshimizu, T., Chaki, S., Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem. Biophys. Res. Commun. 315:2 (2004), 493–496.
136. [136] Kim, S.H., Steele, J.W., Lee, S.W., Clemenson, G.D., Carter, T.A., Treuner, K., Gadient, R., Wedel, P., Glabe, C., Barlow, C., Ehrlich, M.E., Gage, F.H., Gandy, S., Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Abeta oligomer mouse. Mol. Psychiatry 19:11 (2014), 1235–1242.
137. [137] Lee, H.G., Zhu, X., Casadesus, G., Pallas, M., Camins, A., O'Neill, M.J., Nakanishi, S., Perry, G., Smith, M.A., The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Res. 1249 (2009), 244–250.
138. [138] Cartmell, J., Schoepp, D.D., Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem. 75:3 (2000), 889–907.
139. [139] Gasparini, F., Bruno, V., Battaglia, G., Lukic, S., Leonhardt, T., Inderbitzin, W., Laurie, D., Sommer, B., Varney, M.A., Hess, S.D., Johnson, E.C., Kuhn, R., Urwyler, S., Sauer, D., Portet, C., Schmutz, M., Nicoletti, F., Flor, P.J., (R, S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J. Pharmacol. Exp. Ther. 289:3 (1999), 1678–1687.
140. [140] Graham, M.E., Burgoyne, R.D., Activation of metabotropic glutamate receptors by L-AP4 stimulates survival of rat cerebellar granule cells in culture. Eur. J. Pharmacol. 288:1 (1994), 115–123.
141. [141] Bruno, V., Battaglia, G., Ksiazek, I., van der Putten, H., Catania, M.V., Giuffrida, R., Lukic, S., Leonhardt, T., Inderbitzin, W., Gasparini, F., Kuhn, R., Hampson, D.R., Nicoletti, F., Flor, P.J., Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death. J. Neurosci.: Offi. J. Soc. Neurosci. 20:17 (2000), 6413–6420.
142. [142] Bruno, V., Copani, A., Bonanno, L., Knoepfel, T., Kuhn, R., Roberts, P.J., Nicoletti, F., Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur. J. Pharmacol. 310:1 (1996), 61–66.
143. [143] Copani, A., Bruno, V., Battaglia, G., Leanza, G., Pellitteri, R., Russo, A., Stanzani, S., Nicoletti, F., Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol. Pharmacol. 47:5 (1995), 890–897.
144. [144] Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., Delon, M.R., Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215:4537 (1982), 1237–1239.
145. [145] Winkler, J., Suhr, S.T., Gage, F.H., Thal, L.J., Fisher, L.J., Essential role of neocortical acetylcholine in spatial memory. Nature 375:6531 (1995), 484–487.
146. [146] Gu, Z., Cheng, J., Zhong, P., Qin, L., Liu, W., Yan, Z., Abeta selectively impairs mGluR7 modulation of NMDA signaling in basal forebrain cholinergic neurons: implication in Alzheimer's disease. J. Neurosci.: Offi. J. Soc. Neurosci. 34:41 (2014), 13614–13628.
147. [147] Miguel-Hidalgo, J.J., Alvarez, X.A., Cacabelos, R., Quack, G., Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1–40). Brain Res. 958:1 (2002), 210–221.
148. [148] Malinow, R., New developments on the role of NMDA receptors in Alzheimer's disease. Curr. Opin. Neurobiol. 22:3 (2012), 559–563.
149. [149] Cicchetti, F., Drouin-Ouellet, J., Gross, R.E., Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol. Sci. 30:9 (2009), 475–483.
150. [150] Frisina, P.G., Haroutunian, V., Libow, L.S., The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat. Disord. 15:2 (2009), 144–148.
151. [151] Lee, F.J., Liu, F., Genetic factors involved in the pathogenesis of Parkinson's disease. Brain Res. Rev. 58:2 (2008), 354–364.
152. [152] Bartels, A.L., Leenders, K.L., Parkinson's disease: the syndrome, the pathogenesis and pathophysiology. Cortex 45:8 (2009), 915–921.
153. [153] Dauer, W., Przedborski, S., Parkinson's disease: mechanisms and models. Neuron 39:6 (2003), 889–909.
154. [154] Gerlach, M., Riederer, P., Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural. Transm. (Vienna) 103:8-9 (1996), 987–1041.
155. [155] Hornykiewicz, O., Chemical neuroanatomy of the basal ganglia?normal and in Parkinson's disease. J. Chem. Neuroanat. 22:1–2 (2001), 3–12 ().
156. [156] DeLong, M.R., Wichmann, T., Basal ganglia circuits as targets for neuromodulation in parkinson disease. JAMA Neurol. 72:11 (2015), 1354–1360.
157. [157] Benbir, G., Ozekmekci, S., Apaydin, H., Delil, S., Erginoz, E., A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy. Clin. Neurol. Neurosurg. 108:8 (2006), 726–732.
158. [158] Rajput, A.H., Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat. Disord. 8:2 (2001), 95–100.
159. [159] Schapira, A.H., Bezard, E., Brotchie, J., Calon, F., Collingridge, G.L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Le Novere, N., Obeso, J.A., Schwarzschild, M.A., Spampinato, U., Davidai, G., Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 5:10 (2006), 845–854.
160. [160] Lundblad, M., Picconi, B., Lindgren, H., Cenci, M.A., A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 16:1 (2004), 110–123.
161. [161] Picconi, B., Piccoli, G., Calabresi, P., Synaptic dysfunction in Parkinson's disease. Adv. Exp. Med. Biol. 970 (2012), 553–572.
162. [162] Paoletti, P., Molecular basis of NMDA receptor functional diversity. Eur. J. Neurosci. 33:8 (2011), 1351–1365.
163. [163] Nicoletti, F., Bockaert, J., Collingridge, G.L., Conn, P.J., Ferraguti, F., Schoepp, D.D., Wroblewski, J.T., Pin, J.P., Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 60:7-8 (2011), 1017–1041.
164. [164] Amalric, M., Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease. Curr. Opin. Pharmacol. 20 (2015), 29–34.
165. [165] Rylander, D., Recchia, A., Mela, F., Dekundy, A., Danysz, W., Cenci, M.A., Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 330:1 (2009), 227–235.
166. [166] Breysse, N., Baunez, C., Spooren, W., Gasparini, F., Amalric, M., Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci.: Offi. J. Soc. Neurosci. 22:13 (2002), 5669–5678.
167. [167] Coccurello, R., Breysse, N., Amalric, M., Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 29:8 (2004), 1451–1461.
168. [168] Samadi, P., Gregoire, L., Morissette, M., Calon, F., Hadj Tahar, A., Belanger, N., Dridi, M., Bedard, P.J., Di Paolo, T., Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias. Neuropharmacology 54:2 (2008), 258–268.
169. [169] Spooren, W.P., Gasparini, F., Bergmann, R., Kuhn, R., Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. Eur. J. Pharmacol. 406:3 (2000), 403–410.
170. [170] Gasparini, F., Lingenhohl, K., Stoehr, N., Flor, P.J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., Varney, M.A., Johnson, E.C., Hess, S.D., Rao, S.P., Sacaan, A.I., Santori, E.M., Velicelebi, G., Kuhn, R., 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:10 (1999), 1493–1503.
171. [171] Ossowska, K., Konieczny, J., Wardas, J., Pietraszek, M., Kuter, K., Wolfarth, S., Pilc, A., An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids 32:2 (2007), 179–188.
172. [172] Phillips, J.M., Lam, H.A., Ackerson, L.C., Maidment, N.T., Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur. J. Neurosci. 23:1 (2006), 151–160.
173. [173] Litim, N., Morissette, M., Di Paolo, T., Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: an update from the last 5 years of research. Neuropharmacology, 2016.
174. [174] Ambrosi, G., Armentero, M.T., Levandis, G., Bramanti, P., Nappi, G., Blandini, F., Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Res. Bull. 82:1-2 (2010), 29–38.
175. [175] Morin, N., Gregoire, L., Gomez-Mancilla, B., Gasparini, F., Di Paolo, T., Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58:7 (2010), 981–986.
176. [176] Morin, N., Gregoire, L., Morissette, M., Desrayaud, S., Gomez-Mancilla, B., Gasparini, F., Di Paolo, T., MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology 66 (2013), 355–364.
177. [177] Johnston, T.H., Fox, S.H., McIldowie, M.J., Piggott, M.J., Brotchie, J.M., Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1 3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 333:3 (2010), 865–873.
178. [178] Maranis, S., Stamatis, D., Tsironis, C., Konitsiotis, S., Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia. Eur. J. Pharmacol. 683:1–3 (2012), 71–77.
179. [179] Gregoire, L., Morin, N., Ouattara, B., Gasparini, F., Bilbe, G., Johns, D., Vranesic, I., Sahasranaman, S., Gomez-Mancilla, B., Di Paolo, T., The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat. Disord., 17(4), 2011, 270.
180. [180] Bezard, E., Pioli, E.Y., Li, Q., Girard, F., Mutel, V., Keywood, C., Tison, F., Rascol, O., Poli, S.M., The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov. Disord. 29:8 (2014), 1074–1079.
181. [181] Ko, W.K., Pioli, E., Li, Q., McGuire, S., Dufour, A., Sherer, T.B., Bezard, E., Facheris, M.F., Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1 2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Mov. Disord. 29:6 (2014), 772–779.
182. [182] Rylander, D., Iderberg, H., Li, Q., Dekundy, A., Zhang, J., Li, H., Baishen, R., Danysz, W., Bezard, E., Cenci, M.A., A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis. 39:3 (2010), 352–361.
183. [183] Tison, F., Keywood, C., Wakefield, M., Durif, F., Corvol, J.C., Eggert, K., Lew, M., Isaacson, S., Bezard, E., Poli, S.M., Goetz, C.G., Trenkwalder, C., Rascol, O., A phase 2A trial of the novel mGluR5-Negative allosteric modulator dipraglurant for levodopa-Induced dyskinesia in parkinson's disease. Mov. Disord., 2016.
184. [184] Chen, L., Liu, J., Ali, U., Gui, Z.H., Hou, C., Fan, L.L., Wang, Y., Wang, T., Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions. Brain Res. Bull. 84:3 (2011), 215–223.
185. [185] Hsieh, M.H., Ho, S.C., Yeh, K.Y., Pawlak, C.R., Chang, H.M., Ho, Y.J., Lai, T.J., Wu, F.Y., Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. Pharmacol. Biochem. Behav. 102:1 (2012), 64–71.
186. [186] Masilamoni, G.J., Bogenpohl, J.W., Alagille, D., Delevich, K., Tamagnan, G., Votaw, J.R., Wichmann, T., Smith, Y., Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain: A J. Neurol. 134:Pt. 7 (2011), 2057–2073.
187. [187] Fieblinger, T., Sebastianutto, I., Alcacer, C., Bimpisidis, Z., Maslava, N., Sandberg, S., Engblom, D., Cenci, M.A., Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. J. Neurosci.: Offi. J. Soc. Neurosci. 34:13 (2014), 4728–4740.
188. [188] Corti, C., Battaglia, G., Molinaro, G., Riozzi, B., Pittaluga, A., Corsi, M., Mugnaini, M., Nicoletti, F., Bruno, V., The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection. J. Neurosci.: Offi. J. Soc. Neurosci. 27:31 (2007), 8297–8308.
189. [189] Durand, D., Carniglia, L., Caruso, C., Lasaga, M., mGlu3 receptor and astrocytes: partners in neuroprotection. Neuropharmacology 66 (2013), 1–11.
190. [190] Bruno, V., Caraci, F., Copani, A., Matrisciano, F., Nicoletti, F., Battaglia, G., The impact of metabotropic glutamate receptors into active neurodegenerative processes: a dark side in the development of new symptomatic treatments for neurologic and psychiatric disorders. Neuropharmacology, 2016.
191. [191] Di Liberto, V., Bonomo, A., Frinchi, M., Belluardo, N., Mudo, G., Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain. Neuroscience 165:3 (2010), 863–873.
192. [192] Johnson, K.A., Conn, P.J., Niswender, C.M., Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol. Disord. Drug Targets 8:6 (2009), 475–491.
193. [193] Lopez, S., Bonito-Oliva, A., Pallottino, S., Acher, F., Fisone, G., Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease. J. Parkinsons Dis. 1:4 (2011), 339–346.
194. [194] Zhou, F., Hongmin, B., Xiang, Z., Enyu, L., Changes of mGluR4 and the effects of its specific agonist L-AP4 in a rodent model of diffuse brain injury. J. Clin. Neurosci. 10:6 (2003), 684–688.
195. [195] Betts, M.J., O'Neill, M.J., Duty, S., Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease. Br. J. Pharmacol. 166:8 (2012), 2317–2330.
196. [196] Bennouar, K.E., Uberti, M.A., Melon, C., Bacolod, M.D., Jimenez, H.N., Cajina, M., Kerkerian-Le Goff, L., Doller, D., Gubellini, P., Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology 66 (2013), 158–169.
197. [197] Iderberg, H., Maslava, N., Thompson, A.D., Bubser, M., Niswender, C.M., Hopkins, C.R., Lindsley, C.W., Conn, P.J., Jones, C.K., Cenci, M.A., Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology 95 (2015), 121–129.
198. [198] Jones, C.K., Engers, D.W., Thompson, A.D., Field, J.R., Blobaum, A.L., Lindsley, S.R., Zhou, Y., Gogliotti, R.D., Jadhav, S., Zamorano, R., Bogenpohl, J., Smith, Y., Morrison, R., Daniels, J.S., Weaver, C.D., Conn, P.J., Lindsley, C.W., Niswender, C.M., Hopkins, C.R., Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2, 5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. J. Med. Chem. 54:21 (2011), 7639–7647.
199. [199] Le Poul, E., Bolea, C., Girard, F., Poli, S., Charvin, D., Campo, B., Bortoli, J., Bessif, A., Luo, B., Koser, A.J., Hodge, L.M., Smith, K.M., DiLella, A.G., Liverton, N., Hess, F., Browne, S.E., Reynolds, I.J., A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 343:1 (2012), 167–177.
200. [200] Mitsukawa, K., Yamamoto, R., Ofner, S., Nozulak, J., Pescott, O., Lukic, S., Stoehr, N., Mombereau, C., Kuhn, R., McAllister, K.H., van der Putten, H., Cryan, J.F., Flor, P.J., A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:51 (2005), 18712–18717.
201. [201] Broadstock, M., Austin, P.J., Betts, M.J., Duty, S., Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br. J. Pharmacol. 65:4b (2012), 1034–1045.
202. [202] Greco, B., Lopez, S., van der Putten, H., Flor, P.J., Amalric, M., Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 332:3 (2010), 1064–1071.
203. [203] Konieczny, J., Lenda, T., Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082. Pharmacol. Rep. 65:5 (2013), 1194–1203.
204. [204] Thomas, N.K., Wright, R.A., Howson, P.A., Kingston, A.E., Schoepp, D.D., Jane, D.E., (S)-3 4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology 40:3 (2001), 311–318.
205. [205] Johnson, K.A., Jones, C.K., Tantawy, M.N., Bubser, M., Marvanova, M., Ansari, M.S., Baldwin, R.M., Conn, P.J., Niswender, C.M., The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Neuropharmacology 66 (2013), 187–195.
206. [206] Group, H., A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72:6 (1993), 971–983.
207. [207] Ribeiro, F.M., Camargos, E.R., de Souza, L.C., Teixeira, A.L., Animal models of neurodegenerative diseases. Revista brasileira de psiquiatria 35:Suppl. 2 (2013), S82–91.
208. [208] Pouladi, M.A., Morton, A.J., Hayden, M.R., Choosing an animal model for the study of Huntington's disease. Nat. Rev. Neurosci. 14:10 (2013), 708–721.
209. [209] Li, S.H., Li, X.J., Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet.: TIG 20:3 (2004), 146–154.
210. [210] Li, S.H., Schilling, G., Young, W.S. 3rd, Li, X.J., Margolis, R.L., Stine, O.C., Wagster, M.V., Abbott, M.H., Franz Ranen, M.L.N.G., et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11:5 (1993), 985–993.
211. [211] Strong, T.V., Tagle, D.A., Valdes, J.M., Elmer, L.W., Boehm, K., Swaroop, M., Kaatz, K.W., Collins, F.S., Albin, R.L., Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat. Genet. 5:3 (1993), 259–265.
212. [212] Chen, N., Luo, T., Wellington, C., Metzler, M., McCutcheon, K., Hayden, M.R., Raymond, L.A., Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 72:5 (1999), 1890–1898.
213. [213] Schiefer, J., Sprunken, A., Puls, C., Luesse, H.G., Milkereit, A., Milkereit, E., Johann, V., Kosinski, C.M., The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res. 1019:1-2 (2004), 246–254.
214. [214] Zeron, M.M., Hansson, O., Chen, N., Wellington, C.L., Leavitt, B.R., Brundin, P., Hayden, M.R., Raymond, L.A., Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33:6 (2002), 849–860.
215. [215] Beal, M.F., Kowall, N.W., Ellison, D.W., Mazurek, M.F., Swartz, K.J., Martin, J.B., Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321:6066 (1986), 168–171.
216. [216] Hantraye, P., Riche, D., Maziere, M., Isacson, O., A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp. Neurol. 108:2 (1990), 91–104.
217. [217] Sun, Y., Savanenin, A., Reddy, P.H., Liu, Y.F., Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276:27 (2001), 24713–24718.
218. [218] Calabresi, P., Centonze, D., Pisani, A., Bernardi, G., Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease. Exp. Neurol. 158:1 (1999), 97–108.
219. [219] Tang, T.S., Slow, E., Lupu, V., Stavrovskaya, I.G., Sugimori, M., Llinas, R., Kristal, B.S., Hayden, M.R., Bezprozvanny, I., Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 102:7 (2005), 2602–2607.
220. [220] Tang, T.S., Tu, H., Chan, E.Y., Maximov, A., Wang, Z., Wellington, C.L., Hayden, M.R., Bezprozvanny, I., Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1 4,5) triphosphate receptor type 1. Neuron 39:2 (2003), 227–239.
221. [221] Ribeiro, F.M., Paquet, M., Ferreira, L.T., Cregan, T., Swan, P., Cregan, S.P., Ferguson, S.S., Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease. J. Neurosci. 30:1 (2010), 316–324.
222. [222] Ribeiro, F.M., Devries, R.A., Hamilton, A., Guimaraes, I.M., Cregan, S.P., Pires, R.G., Ferguson, S.S., Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease. Hum. Mol. Genet. 23:8 (2014), 2030–2042.
223. [223] Lea, P.M.t., Movsesyan, V.A., Faden, A.I., Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors. Br. J. Pharmacol. 145:4 (2005), 527–534.
224. [224] Bruno, V., Battaglia, G., Copani, A., Cespedes, V.M., Galindo, M.F., Cena, V., Sanchez-Prieto, J., Gasparini, F., Kuhn, R., Flor, P.J., Nicoletti, F., An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors. Eur. J. Neurosci. 13:8 (2001), 1469–1478.
225. [225] Anborgh, P.H., Godin, C., Pampillo, M., Dhami, G.K., Dale, L.B., Cregan, S.P., Truant, R., Ferguson, S.S., Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. J. Biol. Chem. 280:41 (2005), 34840–34848.
226. [226] Baskys, A., Bayazitov, I., Fang, L., Blaabjerg, M., Poulsen, F.R., Zimmer, J., Group I metabotropic glutamate receptors reduce excitotoxic injury and may facilitate neurogenesis. Neuropharmacology 49:Suppl. 1 (2005), 146–156.
227. [227] Blaabjerg, M., Baskys, A., Zimmer, J., Vawter, M.P., Changes in hippocampal gene expression after neuroprotective activation of group I metabotropic glutamate receptors. Brain. Res. Mol. Brain Res. 117:2 (2003), 196–205.
228. [228] Humbert, S., Bryson, E.A., Cordelieres, F.P., Connors, N.C., Datta, S.R., Finkbeiner, S., Greenberg, M.E., Saudou, F., The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2:6 (2002), 831–837.
229. [229] Warby, S.C., Doty, C.N., Graham, R.K., Shively, J., Singaraja, R.R., Hayden, M.R., Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol. Cell. Neurosci. 40:2 (2009), 121–127.
230. [230] Doria, J.G., Silva, F.R., de Souza, J.M., Vieira, L.B., Carvalho, T.G., Reis, H.J., Pereira, G.S., Dobransky, T., Ribeiro, F.M., Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease. Br. J. Pharmacol. 169:4 (2013), 909–921.
231. [231] Chen, T., Cao, L., Dong, W., Luo, P., Liu, W., Qu, Y., Fei, Z., Protective effects of mGluR5 positive modulators against traumatic neuronal injury through PKC-dependent activation of MEK/ERK pathway. Neurochem. Res. 37:5 (2012), 983–990.
232. [232] Loane, D.J., Stoica, B.A., Tchantchou, F., Kumar, A., Barrett, J.P., Akintola, T., Xue, F., Conn, P.J., Faden, A.I., Novel mGluR5 positive allosteric modulator improves functional recovery, attenuates neurodegeneration, and alters microglial polarization after experimental traumatic brain injury. Neurotherapeutics 11:4 (2014), 857–869.
233. [233] Zhang, Y., Rodriguez, A.L., Conn, P.J., Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther. 15:3 (2005), 1212–1219.
234. [234] Doria, J.G., de Souza, J.M., Andrade, J.N., Rodrigues, H.A., Guimaraes, I.M., Carvalho, T.G., Guatimosim, C., Dobransky, T., Ribeiro, F.M., The mGluR5 positive allosteric modulator CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease. Neurobiol. Dis. 73 (2015), 163–173.
235. [235] Lessmann, V., Gottmann, K., Malcangio, M., Neurotrophin secretion: current facts and future prospects. Prog. Neurobiol. 69:5 (2003), 341–374.
236. [236] Poo, M.M., Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2:1 (2001), 24–32.
237. [237] Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R., Timmusk, T., Sipione, S., Cattaneo, E., Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293:5529 (2001), 493–498.
238. [238] Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B.R., Hayden, M.R., Timmusk, T., Rigamonti, D., Cattaneo, E., Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35:1 (2003), 76–83.
239. [239] Gauthier, L.R., Charrin, B.C., Borrell-Pages, M., Dompierre, J.P., Rangone, H., Cordelieres, F.P., De Mey, J., MacDonald, M.E., Lessmann, V., Humbert, S., Saudou, F., Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:1 (2004), 127–138.
240. [240] Zuccato, C., Marullo, M., Conforti, P., MacDonald, M.E., Tartari, M., Cattaneo, E., Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 18:2 (2008), 225–238.
241. [241] Canals, J.M., Pineda, J.R., Torres-Peraza, J.F., Bosch, M., Martin-Ibanez, R., Munoz, M.T., Mengod, G., Ernfors, P., Alberch, J., Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24:35 (2004), 7727–7739.
242. [242] Gharami, K., Xie, Y., An, J.J., Tonegawa, S., Xu, B., Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 105:2 (2008), 369–379.
243. [243] Xie, Y., Hayden, M.R., Xu, B., BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci. 30:44 (2010), 14708–14718.
244. [244] Giralt, A., Carreton, O., Lao-Peregrin, C., Martin, E.D., Alberch, J., Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction. Mol. Neurodegen., 6(1), 2011, 71.
245. [245] Pisani, A., Bernardi, G., Bonsi, P., Centonze, D., Giacomini, P., Calabresi, P., Cell-type specificity of mGluR activation in striatal neuronal subtypes. Amino Acids 19:1 (2000), 119–129.
246. [246] Testa, C.M., Friberg, I.K., Weiss, S.W., Standaert, D.G., Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. J. Comp. Neurol. 390:1 (1998), 5–19.
247. [247] Reiner, A., Wang, H.B., Del Mar, N., Sakata, K., Yoo, W., Deng, Y.P., BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice. Brain Res. 1473 (2012), 161–172.